Key facts
- Cirrus Therapeutics’s last known valuation is $26.0M (Oct 2025).
- It has raised $11.0M across 1 recorded rounds; the latest was Early Stage VC ($6.7M) in Aug 2025.
- Notable investors include The Engine, SEEDS Capital, Polaris Partners, ZAKA VC, University of Bristol — 8 tracked in total.
- Cirrus Therapeutics has filed 1 Form D with the SEC, most recently Aug 2025 ($6.7M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Cirrus Therapeutics
Funding rounds
1 roundsAbout Cirrus Therapeutics
Developer of gene therapies intended to create ocular immunology treatments for age-related macular degeneration. The company offers gene therapy programs, ocular immunology research, IRAK-M modulation technology, viral vector delivery methods, and preclinical development, enabling healthcare stakeholders access to biomedical approaches targeting vision loss.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 5
- Website
- cirrustx.com/
- Ownership
- Privately Held (backing)
Cirrus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cirrus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cirrus Therapeutics in its N-PORT filings yet. We sweep new filings monthly.